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Background: Hepatectomy is the standard treatment for HCC. However, large HCC poses a difficult challenge
because of the technical complexity of surgical resection and the fear of postoperative hepatic decompensation.
We analyzed the outcome and prognostic factors in patients with large hepatocellular carcinoma (HCC ≥10 cm)
after surgery.
Methods: We retrospectively investigated the medical records of 91 patients who had undergone hepatectomy
between January 2006 and June 2010. A survival analysis was performed utilizing the Kaplan-Meier method and
prognostic factors were evaluated using Cox regression analysis.
Results: Of the 91 patients evaluated, most tumors were associated with hepatitis B virus (HBV). The median tumor
size was 12.3 cm (range, 10 to 21 cm), with microvascular invasion present in most patients. The postoperative
mortality rate was 2.2%. The median disease-free survival and overall survival were six months and 41 months. The
one-year, two-year, and three-year disease-free survival rates were 33.5%, 29.3%, and 18.8%, respectively. The one-
year, two-year, and three-year overall survival rates were 73.9%, 63.7%, and 54.8%, respectively. Of the 89 surviving
patients, 69 patients (77.5%) developed HCC recurrence during the mean follow-up period of 23.4 ± 15.9 months.
On multivariate analysis, the statistically significant factors that predicted HCC recurrence were ALP ≥ 80 IU/mL
(P = 0.009) and intrahepatic metastases (P = 0.013).
Conclusions: Our study suggests that preoperative ALP levels (≥ 80 IU/L) and intrahepatic metastases could be
utilized to monitor and predict recurrence in HCC patients.
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Hepatectomy has been widely accepted as the main
strategy for the treatment of resectable hepatocellular
carcinoma (HCC) based upon the proven impact of ad-
equate tumor removal on prognosis. However, there
continues to be debate regarding the extent of necessary
resection, as well as the balance between the risks of in-
adequate parenchymal preservation and the benefits of
oncologic clearance [1].* Correspondence: jw.joh@samsung.com
1Department of Surgery, Samsung Medical Center, Sungkyunkwan University
School of Medicine, #50 Ilwon-Dong Gangnam-Gu, Seoul 135-710, Korea
Full list of author information is available at the end of the article
© 2013 Kim et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orDespite recent advances in imaging modalities and the
application of a screening program in high risk
populations, such as in areas where hepatitis B is en-
demic, large HCC (≥ 10 cm in diameter) is still fre-
quently encountered in clinical practice [2].
Large HCC poses a difficult challenge because of the
technical complexity of surgical resection and the fear of
postoperative hepatic decompensation, especially when
associated with advanced cirrhosis. Treatment options
for large HCC are limited. Liver transplantation is not
an accepted modality for the treatment of large HCC
due to issues of organ allocation and the high rates of
tumor recurrence [3]. Transarterial chemoembolization
(TACE) is an attractive option for large HCC, but the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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outcomes are not well known [4]. At present, provided
the patient’s hepatic functional reserve is acceptable for
resection, hepatectomy is considered the best option in
patients with HCC ≥ 10 cm because it is potentially
curative and can be performed safely with acceptable
morbidity [5-7].
However, tumor recurrence is common after resection
of large HCC [8,9], possibly due to unrecognized small
vessel tumor invasion [5], and may signify a worse out-
come as a result of currently unidentified genetic factors
[10]. Overall patient survival after hepatectomy usually
depends upon the outcome following the liver resection,
as well as additional treatments for recurrence.
We retrospectively analyzed the long-term outcomes
of patients with large HCC following hepatectomy at a
single center and evaluated the prognostic factors that
influenced tumor recurrence in these patients.
Methods
Patients
From January 2006 to June 2010, 91 patients with large
HCC (≥ 10 cm in diameter) underwent hepatectomy at
Samsung Medical Center. Younger patients (< 18 years
of age), pathologically-proven mixed hepatocellular car-
cinoma and cholangiocarcinoma, and patients who were
lost to follow-up after the hepatectomy were excluded
from this study. The demographics, preoperative labora-
tory results, and pathologic data of all of the patients
were collected from the electronic medical records
(EMR) and retrospectively reviewed. Liver function was
evaluated using the Child-Pugh classification system.
Surgery and pathology
Preoperative evaluation of liver function included serum
levels of bilirubin, transaminases, alkaline phosphatase,
albumin, and prothrombin time. Selection criteria for
the hepatectomy depended on the extent and location of
the tumor, liver function, indocyanine green retention
(ICG) test results, and the volume of the future liver
remnant. Child-Pugh class C, severe comorbidity, and
distant metastases were considered contraindications for
hepatectomy.
A standard operative technique for hepatectomy was
utilized for these tumors. Depending on the part of the
liver to be resected, adequate mobilization was performed.
An anterior approach was used in patients for whom right
lobe mobilization was considered hazardous [11]. Selective
clamping of the portal vein and hepatic artery was
performed when feasible. If this was not possible, an inter-
mittent Pringle maneuver was performed instead. Paren-
chymal transection was performed using CUSA (Cavitron
Ultrasonic Surgical Aspirator) under low central venous
pressure.Postoperative histological assessment and reporting
included the maximal tumor diameter, capsular forma-
tion, capsular invasion, portal vein invasion, bile duct
invasion, microvascular invasion, serosa involvement,
intrahepatic metastasis, multicentric occurrence of HCC
and others. Intrahepatic metastasis and multicentric
occurrence were defined based on guidelines from the
Liver Cancer Study Group of Japan [12]. Histologic
grade of HCC was assessed according to the Edmonson-
Steiner grading system [13], and grouped as well-
differentiated (grade I), moderately-differentiated (grade
II), or poorly-differentiated (grades III and IV).Surveillance after surgical resection
Postoperative mortality was defined as all deaths within
30 days of hepatectomy. After surgery, patients were
followed postoperatively every two to three months.
Follow-up parameters included physical examination,
serum alpha-fetoprotein (AFP), protein induced by vita-
min K antagonist II (PIVKA-II), liver function tests, and
chest x-rays. Abdominal computed tomography (CT)
was performed every three months or when recurrence
was suspected. Magnetic resonance imaging (MRI) and/
or positron emission tomography (PET) scans were
performed if CT did not show definitive evidence of re-
currence. Detailed information on patients found to have
a recurrence was recorded. Patients with intrahepatic
recurrences were treated with radiofrequency ablation
(RFA), TACE, or sorafenib according to their functional
liver reserve and the pattern of recurrence. The follow-
up time was considered to be the length of time from
the surgery to the last follow-up (1 December 2011) or
death. No patients were lost to follow-up and all 91
patients were included in the survival analysis.Statistical analysis
All data were analyzed using SPSS statistical software
(Version 19.0; SPSS Inc., Chicago, IL, USA). Continu-
ous variables were presented as median and range and
compared by using the Mann–Whitney U test. Cat-
egorical variables were compared using Fisher’s exact
test. The arbitrary cut-off value in each continuous
variable was determined by the receiver operating
characteristics (ROC) curve. The disease-free survival
rates and overall survival rates were calculated with the
Kaplan-Meier method and compared using the log-
rank test. Univariate analyses were performed to iden-
tify risk factors of HCC recurrence in large HCC using
a Cox regression model. A backward multivariate ana-
lysis was performed using a Cox proportional hazard
model on all variables that were significantly associated
with survival on univariate analysis. A P-value < 0.05
was considered statistically significant.
Table 1 Clinicopathologic features and surgical










non-B, non-C 21 (23.1%)
Others 3 (3.3%)
AFP (ng/dL)
< 1000 58 (63.7%)
≥ 1000 33 (36.3%)
PIVKA-II (mAU/mL)
< 200 28 (30.8%)
≥ 200 63 (69.2%)
White blood cells (/uL) 6,040 (2,100 to 10,790)
Hemoglobin (g/dL) 14.2 (8.1 to 17.0)
Platelet counts (/uL) 205,000 (61,000 to 627,000)
INR 1.07 (0.91 to 1.31)
Albumin (g/dL) 4.0 (2.9 to 5.0)
Total bilirubin (mg/dL) 0.7 (0.3 to 1.2)
AST (U/L) 43 (14 to 353)
ALT (U/L) 39 (12 to 385)
ALP (U/L) 92 (38 to 287)
Creatinine (mg/dL) 0.89 (0.65 to 2.99)
Maximum tumor size (cm) 12.3 (10 to 21)
Cirrhosis 17 (18.7%)
Grade
1 and 2 75 (82.4%)
3 and 4 16 (17.6%)
Capsular invasion 77 (84.6%)
Microvascular invasion 85 (93.4%)
Portal vein invasion 19 (20.9%)
Bile duct invasion 4 (4.4%)
Serosa involvement 8 (8.8%)
Intrahepatic metastasis 30 (33.0%)
Multicentric occurrence 5 (5.5%)
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; PIVKA-II,
protein induced by vitamin K antagonist-II; TACE, transarterial
chemoembolization; INR, international normalized ratio; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
Kim et al. World Journal of Surgical Oncology 2013, 11:40 Page 3 of 8
http://www.wjso.com/content/11/1/40Results
Patient demographics and tumor characteristics
Clinicopathological features of the 91 patients are
summarized in Table 1. All patients were Child-Pugh
class A and none received preoperative radiation. The
majority of the patients were male (87.9%) and the me-
dian age was 52 years (range, 19 to 82). The etiology of
most of the HCC cases was hepatitis B virus (HBV). The
median AFP and PIVKA-II were 134.4 ng/mL (range,
1.8 to 200,000 ng/mL) and 500 mAU/mL (range, 5 to
2000 mAU/mL), respectively. Eighteen patients (19.8%)
were treated with TACE prior to hepatic resection.
Perioperative and postoperative characteristics were






Right hepatectomy 55 (60.4%)
Left hepatectomy 1 (1.1%)
Posterior segmentectomy 2 (2.2%)
Anterior segmentectomy 1 (1.1%)
Extended right hepatectomy 11 (12.1%)
Extended left hepatectomy 3 (3.3%)
Left lateral segmentectomy 5 (5.5%)
Central hepatectomy 2 (2.2%)
Segmentectomy 11 (12.1%)
Blood loss during operation (mL) 550 (100 to 4000)
Operation time (minutes) 330 (150 to 720)
Postoperative
Morbidity
Wound infection 6 (6.6%)
Atelectasis 8 (8.8%)
Pneumonia 2 (2.2%)
Pleural effusion 4 (4.4%)
Bile leakage 6 (6.6%)
Ascites 8 (8.8)
Delirium 1 (1.1%)
Hepatic failure 1 (1.1%)
Hyperbilirubinemia 1 (1.1%)
Mechanical obstruction 1 (1.1%)
Portal vein thrombosis 1 (1.1%)
Spontaneous bacterial peritonitis 1 (1.1%)
Wound dehiscence 2 (2.2%)
Mortality 2 (2.2%)
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to 4000 mL) and 330 minutes (150 to 720 minutes),
respectively.
The median tumor size was 12.3 cm (range, 10 to 21
cm). Portal vein invasion and bile duct invasion were
detected in 19 (20.9%) and 4 (4.4%) patients, respect-
ively. Microvascular invasion was seen in 85 patients
(93.4%) and capsular invasion was seen in 77 patients
(84.6%). Intrahepatic metastasis and multicentric occur-
rence were detected in 30 (33.0%) and 5 patients (5.5%),
respectively.
Eight-nine of the 91 patients recovered from hepa-
tectomy, while two died from liver failure after the
surgery. The median length of hospitalization after
hepatectomy was ten days (range, seven to fifty-three
days) and the mean duration of follow-up was 23.4 ±
15.9 months.Survival
The median disease-free survival and overall survival of
the patients who underwent resection for large HCC
were six and 41 months, respectively. The one-year, two-
year, and three-year disease-free survival rates were
33.5%, 29.3%, and 18.8%, respectively. The one-year,Figure 1 Disease-free survival and overall survival curves for patients
larger than 10 cm in diameter.two-year, and three-year overall survival rates were
73.9%, 63.7%, and 54.8%, respectively (Figure 1).Recurrence of hepatocellular carcinoma
Of the 89 surviving patients, 69 patients (77.5%)
developed a HCC recurrence during a mean follow-up
of 23.4 ± 15.9 months. Twenty-one of the 69 (30.4%)
presented initially with an isolated intrahepatic recur-
rence, 14 patients (20.3%) presented with an extrahepatic
recurrence, and 34 patients (49.3%) presented with con-
current intrahepatic and extrahepatic recurrences. The
lung (n = 29, 42.0%) and liver (n = 27, 39.1%) were the
main recurrence sites. Sixty-three (91.3%) of the 69
patients received treatments, such as TACE, RFA, and
sorafenib, after tumor recurrence. No patients received
selective internal radiation therapy after recurrence.Prognostic factors
Univariate analysis of prognostic factors for disease-free
survival following hepatic resection in patients with large
HCC identified AFP ≥ 1000 ng/mL, decreased serum al-
bumin levels, increased ALP (normal range, 53 to 128
IU/mL) levels, and intrahepatic metastases as statistically
significant factors determining poor prognosis (Table 3).who underwent hepatic resection of hepatocellular carcinoma
Table 3 Univariate analysis of risk factors related to tumor recurrence in patients with large HCC after hepatic
resection
Variables Odds ratio 95% confidence interval P-value
Gender - Female 1.076 0.531 to 2.182 0.838
Age 0.999 0.980 to1.019 0.933
AFP ≥ 1000 1.935 1.179 to 3.176 0.009
PIVKA-II ≥ 200 1.136 0.677 to 1.906 0.630
White blood cells 0.933 0.813 to 1.071 0.325
Hemoglobin 0.884 0.782 to 1.001 0.051
Platelet count 1.002 1.000 to 1.004 0.075
INR 2.822 0.154 to 51.533 0.484
Albumin 0.443 0.231 to 0.850 0.014
Total bilirubin 1.162 0.570 to 2.367 0.680
AST 1.002 0.998 to 1.006 0.313
ALT 1.000 0.996 to 1.004 0.919
ALP > 80 IU/mL 2.216 1.282 to 3.830 0.004
Glucose 0.998 0.993 to 1.004 0.998
Creatinine 0.787 0.368 to 1.683 0.537
Type of operation (non-anatomical) 1.402 0.711 to 2.768 0.330
Maximum tumor size 0.990 0.990 to 1.008 0.780
Cirrhosis 1.690 0.926 to 3.084 0.087
Grade (3 and 4) 1.141 0.612 to 2.130 0.678
Capsular invasion 0.532 0.277 to 1.020 0.057
Microvascular invasion 1.812 0.566 to 5.797 0.317
Portal vein invasion 1.642 0.933 to 2.889 0.085
Bile duct invasion 1.184 0.371 to 3.785 0.775
Serosa involvement 1.142 0.457 to 2.851 0.776
Intrahepatic metastasis 2.019 1.265 to 3.517 0.004
Multicentric occurrence 0.481 0.118 to 1.966 0.308
AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K antagonist-II; TACE, transarterial chemoembolization; INR, international normalized ratio; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
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anatomical), tumor size, tumor grade, capsular invasion,
microvascular invasion, portal vein invasion, bile duct
invasion, serosa involvement, and multicenteric occur-
rence were not statistically significant. On multivariate
analysis, the statistically significant factors predicting HCC
recurrence were ALP ≥ 80 IU/mL (odds ratio (OR), 2.075;
95% confidence interval (CI), 1.197 to 3.599; P = 0.009)
and intrahepatic metastases (OR, 1.924; 95% CI, 1.149 to
3.221; P = 0.013). The impact of ALP and intrahepatic me-
tastases are depicted in Figure 2.
ALP levels and intrahepatic metastases in patients
We compared the 24 patients who had neither of the
two risk factors (ALP ≥ 80 IU/L or intrahepatic metasta-
ses) with the 67 patients who had at least one risk factor.
Those with no risk factors had a one-year disease-freesurvival rate of 63.6% and a one-year overall survival rate
of 91.5%. In contrast, the patients with at least one risk
factor had a one-year disease-free survival rate of 20.6%
and a one-year overall survival rate of 72.3% (Figure 3).
The differences in the disease-free survival and overall
survival rates were statistically significant (P < 0.001 and
P = 0.003, respectively).
Discussion
During the past decade, hepatectomy for large HCC has
evolved into a safe procedure with a low operative mortal-
ity [7,14]. The 30-day mortality rate of 2.2% (n = 2) in this
study is lower than that reported in general, which is
roughly 5 to 10% [15]. Among postoperative mortality
cases, one case had undergone left extended hepatectomy
with the cause of death being right hepatic artery dissec-
tion during Pringle’s maneuver. Although the right hepatic
Figure 2 (A) Influence of ALP levels and (B) intrahepatic
metastasis on disease-free survival.
Figure 3 (A) Disease free survival and (B) overall survival in
patients with no risk factors when compared with those who
had at least one risk factor.
Kim et al. World Journal of Surgical Oncology 2013, 11:40 Page 6 of 8
http://www.wjso.com/content/11/1/40artery had been anastomosed with the right gastroepiploic
artery, liver failure developed. The other case had under-
gone right hepatectomy and although the preoperative
ICG test was 16.7%, liver failure developed after the
hepatectomy.
However, the long-term survival remains unsatisfac-
tory predominately because of the high incidence of re-
currence and metastases after hepatectomy [16]. Our
study also revealed a high incidence of recurrence withone-year, two-year, and three-year disease-free survival
rates of 33.5%, 29.3%, and 18.8%, respectively.
The greater sizes of these larger HCCs indicate that
the lesion is already advanced, with a greater possibility
of tumor spread, including the existence of satellite
nodules or macrovascular invasion [5]. Such advanced
tumors carry a higher risk of recurrence even after
hepatectomy, such that the benefit of hepatic resection
becomes marginal [17].
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operative care, there has been a significant improvement in
the postoperative outcome for patients following liver re-
section in large volume centers [2,18]. This has encouraged
surgeons to consider surgical resection for large tumors.
We followed an aggressive policy of surgical resection in
the patients with large HCC as we felt that it provided
significant local control with a good quality of life and the
potential for cure in an otherwise hopeless situation. In the
present study, the three-year overall survival rate was
54.8%, indicating an improved outcome when compared
with rates of between 16.7% and 33% in recent reports
[1,2,7,14,17-19].
The size of HCC has traditionally been considered an
important risk factor for patient survival. However, the
size of a single HCC mass in the absence of vascular in-
vasion is no longer regarded as a critical factor [20]. Fur-
thermore, in 2005, the American Association for the
Study of Liver Disease suggested that the size of a tumor
alone is not a limiting factor for surgical resection [21].
A non-cirrhotic liver can tolerate resection of up to 80%
of its volume. The regenerative capacity of the liver
enables functional compensation within a few weeks
with regeneration of approximately 75% of the preopera-
tive liver volume within one year [22,23].
Mok et al. reported that extrahepatic recurrence oc-
curred in 43.4% patients [17], while Poon et al. reported
that extrahepatic recurrence was significantly more fre-
quent in patients with hepatic resection for HCC ≥ 10
cm (31.9%) than those with HCC < 10 cm (12.8%) [6].
Recently, Yamashita et al. reported that extrahepatic re-
currence, such as lung, bone, brain, and peritoneum,
was significantly more frequent in patients with hepatic
resection for HCC ≥ 10 cm than those for HCC < 10 cm
[24]. The present study reported that about two-thirds
of initial HCC recurrences were extrahepatic (with or
without intrahepatic recurrence), while the other one-
third were isolated intrahepatic recurrences.
TACE has been used after surgery to treat intrahepatic
HCC recurrence, particularly in patients with a multi-
focal recurrence within the remaining liver [25]. Percu-
taneous RFA is another safe and effective procedure for
treating intrahepatic recurrences [26]. Repeat liver resec-
tion is indicated for patients with well-preserved liver
function [6,25]. In our study, 8.7% (n = 6) of patients
with recurrent HCC were not treated for tumor recur-
rence because of poor general condition or rapid tumor
spread to multiple organs.
Increased preoperative serum ALP levels and intrahepatic
metastasis were predisposing factors for tumor recurrence
after hepatectomy in patients with large HCC. The tumor
size, differentiation of the tumor, and the margin of resec-
tion were not significant predictors of tumor recurrence.
The small number of patients with a positive margin (n =5) in our study makes it difficult to draw a firm conclusion
regarding the importance of margins.
Intrahepatic metastasis is thought to be the main
mechanism of early recurrence based on histological
analysis of tumor recurrence [27]. ALT is a well-known
marker of inflammatory necrosis in the liver [28,29].
Persistent inflammation will not only cause necrosis and
regeneration of hepatocytes, thereby leading to DNA in-
stability in the hepatocytes and causing the HCC to
occur more frequently, but will also enhance the devel-
opment of intrahepatic metastasis by up-regulating the
expression of vascular adhesion molecules [30]. There-
fore, suppression of ALT elevation by treatment with
anti-inflammatory drugs has been proven to delay recur-
rence after hepatectomy, thereby providing an important
strategy for the prevention of early recurrence [31,32].
Hepatocarcinogenesis by HBV is associated with ALP as
an inflammatory marker. Cumulative data derived from
Asian populations with HCC revealed that elevation of
the ALP level was associated with poor outcomes [33,34].
A large-scale study in Taiwan demonstrated that ALP
could predict the outcome, while a Western study of
Asian Americans with HCC also reported that AFP and
ALP were independent predictors of survival [33,34].
Conclusions
In conclusion, hepatectomy for large HCC is safe in
carefully selected patients. However, we expect a greater
likelihood of early tumor recurrences in patients with
large HCC who have high preoperative ALP levels (≥ 80
IU/L) and intrahepatic metastases after hepatectomy.
Our study suggests that preoperative ALP levels and
intrahepatic metastases could be utilized to monitor and
predict recurrence in HCC patients.
Abbreviation
HCC: Hepatocellular carcinoma; EMR: Electronical medical records;
ICG: Indocyanine green; CUSA: Cavitron Ultrasonic Surgical Aspirator;
AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K antagonist II;
CT: Computed tomography; MRI: Magnetic resonance imaging; PET: Positron
emission tomography; RFA: Radiofrequency ablation; TACE: Transarterial
chemoembolization; ROC: Receiver operating characteristics; ALP: Alkaline
phosphotase.
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